Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
Liminatus Pharma has engaged Synex Consulting Ltd. as the contract research organization to conduct Phase 1/2a clinical trials of its investigational CD19xCD22 bivalent CAR-T therapy (IBC101) targeting relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The engagement supports clinical trial execution in South Korea following regulatory a…